OXO-001 (fertility drug)

2024: Product Announcement

In early July 2024, a new drug called OXO-001 was introduced, increasing the likelihood of successful embryo implantation during in vitro fertilization (IVF). According to Spanish biotech company Oxolife, which developed this oral drug, OXO-001 increases the rate of live babies born after IVF by 7%.

OXO-001 uses a completely new mechanism of action. Unlike other fertility drugs that use hormones, OXO-001 is a non-hormonal drug and affects the endometrium directly, increasing its susceptibility to the embryo during the implantation period.

Unsplash

The effectiveness of OXO-001 was evaluated in a study conducted at 28 clinical centers in Europe. The study involved 96 women under the age of 40 who had a single embryo transferred to them. Treatment was initiated one menstrual cycle before embryo transfer and continued for five subsequent weeks. The pregnancy rate (76%) was significantly higher in the drug group than in the placebo group (52%).

This is an important step in the development of in vitro fertilization technologies and good news for many couples suffering from infertility. The developers hope that further research will confirm these promising results in a wider sample of patients. The company is also exploring using OXO-001 to treat other fertility-related diseases, such as polycystic ovary syndrome.

Despite continuous developments in ovarian stimulation and embryo manipulation, the effectiveness of assisted reproductive technologies is growing very slowly. A jump of almost 7% is very good news for our patients, and we hope that these data will soon be confirmed in larger studies, "Professor Karen Sermon, Chairman of the European Society for Reproductive Technologies and Embryology (ESHRE), noted in a press release[1]

Notes